VERTEX PHARMACEUTICALS INC / MA Increase (Decrease) in Restricted Cash
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Increase (Decrease) in Restricted Cash of -$22.03 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-23.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInRestrictedCash · last filed 2017-02-23
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in restricted cash for the quarter ending 2016-12-31 was -$22.03M, a 2203300.00% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in restricted cash for the quarter ending 2016-09-30 was $3.00K, a 40.00% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in restricted cash for the quarter ending 2016-06-30 was -$3.00K, a 175.00% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in restricted cash for the quarter ending 2016-03-31 was $3.00K, a 99.99% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in restricted cash for fiscal 2016 was -$22.03M, a 200.22% decline from fiscal 2015.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in restricted cash for fiscal 2015 was $21.98M.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in restricted cash for fiscal 2014 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in restricted cash for fiscal 2013 was -$31.80M.
| Period end | Increase (Decrease) in Restricted Cash 3 month | Increase (Decrease) in Restricted Cash 6 month | Increase (Decrease) in Restricted Cash 6 month as first filed | Increase (Decrease) in Restricted Cash 9 month | Increase (Decrease) in Restricted Cash 9 month as first filed | Increase (Decrease) in Restricted Cash 12 month |
|---|---|---|---|---|---|---|
| 2016-12-31 | -$22.03M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | -$22.03M derived: sum of 2 quarters · filed 2017-02-23 | -$22.03M derived: sum of 3 quarters · filed 2017-02-23 | -$22.03M 10-K · filed 2017-02-23 | ||
| 2016-09-30 | $3.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-31 | $0.00 derived: sum of 2 quarters · filed 2016-10-31 | $3.00K 10-Q · filed 2016-10-31 | $4.00K derived: sum of 4 quarters · filed 2017-02-23 | ||
| 2016-06-30 | -$3.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-01 | $0.00 10-Q · filed 2016-08-01 | $1.00K derived: sum of 3 quarters · filed 2017-02-23 | $6.00K derived: sum of 4 quarters · filed 2017-02-23 | ||
| 2016-03-31 | $3.00K 10-Q · filed 2016-05-03 | $4.00K derived: sum of 2 quarters · filed 2017-02-23 | $9.00K derived: sum of 3 quarters · filed 2017-02-23 | $13.00K derived: sum of 4 quarters · filed 2017-02-23 | ||
| 2015-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | $6.00K derived: sum of 2 quarters · filed 2017-02-23 | $10.00K derived: sum of 3 quarters · filed 2017-02-23 | $21.98M 10-K · filed 2017-02-23 | ||
| 2015-09-30 | $5.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-31 | $9.00K derived: sum of 2 quarters · filed 2016-10-31 | $21.98M 10-Q · filed 2016-10-31 | $21.99M derived: sum of 4 quarters · filed 2017-02-23 | ||
| 2015-06-30 | $4.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-01 | $21.98M 10-Q · filed 2016-08-01 | $21.98M derived: sum of 3 quarters · filed 2017-02-23 | $21.98M derived: sum of 4 quarters · filed 2017-02-23 | ||
| 2015-03-31 | $21.97M 10-Q · filed 2016-05-03 | $21.98M derived: sum of 2 quarters · filed 2017-02-23 | $21.97M derived: sum of 3 quarters · filed 2017-02-23 | |||
| 2014-12-31 | $9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | $1.00K derived: sum of 2 quarters · filed 2017-02-23 | $0.00 10-K · filed 2017-02-23 | |||
| 2014-09-30 | -$8.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-30 | -$9.00K 10-Q · filed 2015-10-30 | ||||
| 2014-06-30 | -$1.00K 10-Q · filed 2015-08-04 | |||||
| 2013-12-31 | $3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-16 | $8.00K derived: sum of 2 quarters · filed 2016-02-16 | -$31.80M 10-K · filed 2016-02-16 | |||
| 2013-09-30 | $5.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | -$31.81M 10-Q · filed 2014-11-06 | ||||
| 2013-06-30 | -$31.81M 10-Q · filed 2014-07-31 | |||||
| 2012-12-31 | -$233.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13 | -$2.16M derived: sum of 2 quarters · filed 2015-02-13 | -$2.16M 10-K · filed 2015-02-13 | |||
| 2012-09-30 | -$1.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | -$1.92M 10-Q · filed 2013-11-07 | ||||
| 2012-06-30 | $0.00 10-Q · filed 2013-08-02 | |||||
| 2011-12-31 | -$29.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-11 | -$24.00K derived: sum of 2 quarters · filed 2014-02-11 | -$21.00K derived: sum of 3 quarters · filed 2014-02-11 | $0.00 10-K · filed 2014-02-11 | ||
| 2011-09-30 | $5.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | $8.00K derived: sum of 2 quarters · filed 2012-11-06 | $29.00K 10-Q · filed 2012-11-06 | -$13.96M 10-Q · filed 2011-11-03 | $29.00K derived: sum of 4 quarters · filed 2013-03-01 | |
| 2011-06-30 | $3.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-08 | $24.00K 10-Q · filed 2012-08-08 | -$1.45M 10-Q · filed 2011-08-09 | $24.00K derived: sum of 3 quarters · filed 2013-03-01 | $24.00K derived: sum of 4 quarters · filed 2013-03-01 | |
| 2011-03-31 | $21.00K 10-Q · filed 2012-05-10 | $21.00K derived: sum of 2 quarters · filed 2013-03-01 | $21.00K derived: sum of 3 quarters · filed 2013-03-01 | |||
| 2010-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-01 | $0.00 derived: sum of 2 quarters · filed 2013-03-01 | $3.78M 10-K · filed 2013-03-01 | |||
| 2010-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-03 | $3.78M 10-Q · filed 2011-11-03 | ||||
| 2010-06-30 | $3.78M 10-Q · filed 2011-08-09 | |||||
| 2009-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-22 | $55.00K 10-K · filed 2012-02-22 | ||||
| 2009-09-30 | $55.00K 10-Q · filed 2010-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |